All lobbying filings

Marshall & Popp, LLC

Marshall & Popp, LLC filed a Q2 report for Jazz Pharmaceuticals, Inc. and Its Subsidiaries, Including Greenwich Biosciences on July 21, 2025, reporting $40,000 in lobbying income.

Lobbying for Jazz Pharmaceuticals, Inc. and Its Subsidiaries, Including Greenwich Biosciences · Pharmaceuticals.

As filed: MARSHALL & POPP, LLC for JAZZ PHARMACEUTICALS, INC. AND ITS SUBSIDIARIES, INCLUDING GREENWICH BIOSCIENCES.

All filings by Marshall & Popp, LLC · Everything Jazz Pharmaceuticals, Inc. and Its Subsidiaries, Including Greenwich Biosciences has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 21, 2025

Income

$40,000

What the client paid this registrant for the period.

Client based in

California

Official filing document

Lobbyists on this filing 2

HAZEN CLAY MARSHALL

Previously held: Policy Director-Senate Majority Leader Mitch McConnell; Staff Director/Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant-Senator Don Nickles
MONICA POPP

Previously held: Chief of Staff/Deputy Chief of Staff, Office of Senate Republican Whip John Cornyn; Professional Staff Member, U.S. House of Representatives-Energy & Commerce Committee; Legislative Assistant, Senator Jim DeMint

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Budget/Appropriations

Issues related to budget reconciliation, including H.Con.Res. 14.

Health Issues

Issues related to the research and development of cannabis-derived therapies and FDA's regulatory framework for CBD. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug value, including H.R. 1, FY25 budget reconciliation, implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the regulation of hemp-derived cannabinoids, including H.R. 4121, FY26 Agriculture, FDA and Related Agencies Appropriations. H.R.946 - ORPHAN Cures Act.

Bills named in this filing 4

H. Con. Res. 14
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…
H.R. 1
One Big Beautiful Bill Act
H.R. 4121
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
H.R. 946
ORPHAN Cures Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.